OncoOne Targets Cancer-Related Isoform, OxMIF, In Multiple Ways
Lead Compound Could Be Clinic-Ready By 2022
Executive Summary
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.